Cambridge Healthtech Institute’s 5th Annual
Leveraging RWD for Clinical and Observational Research
RWD Innovation and Technologies
February 20-21, 2020
The abundance of data generated during routine health care is growing in significance and should be used for clinical and observational research. Patient electronic records, registries, data from pharmacy and social media, and wearable sensors have been
increasingly used as eSources. This process requires strategizing, implementing novel data technologies, as well as close collaboration between pharmaceutical companies and organizations that possess the data. CHI’s 5th Annual Leveraging RWD
for Clinical and Observational Research conference will discuss innovative approaches and technologies for RWD-based clinical and observational studies.
Arrive early and attend Part 1 (Wed - Thurs): Accessing and Generating RWD
Final Agenda
Thursday, February 20
11:30 am Registration Open (Regency Rotunda)
12:30 pm BRIDGING LUNCHEON PRESENTATION: Supercharge Study Design and Feasibility: AI with Integrated RWD and Cross-Industry Clinical Trial Data/Metrics
Jef Benbanaste, Senior Director, Product Lead, Acorn AI by Medidata, a Dassault Systèmes company
While RWD can support both clinical and operational trial planning, its value is maximized when analyzed together with data and metrics from a large set of cross-industry clinical trials. This session will share perspectives on how to select fit-for-use
RWD sources, manage and transform RWD, and apply analytics in conjunction with clinical trial data for use cases such as Synthetic Controls, protocol optimization, and site feasibility.
1:00 Coffee and Dessert Break in the Exhibit Hall (Windermere Ballroom)
2:00 Afternoon Plenary Keynotes (Regency Ballroom S)
3:10 Booth Crawl & Refreshment Break in the Exhibit Hall. Last Chance for Exhibit Viewing (Windermere Ballroom)
4:10 Chairperson’s Remarks
Marc Berger, MD, Scientific Advisor, Medidata, a Dassault Systèmes Company
4:15 NEW: Novel Approaches in Real World Data Collection and Analysis
Charles Makin,
Global Head, Real World Evidence Strategy, Biogen
With the growing demand for new medicines to meet critical healthcare needs with speed and efficiency, it has become essential to explore novel approaches and data sources. Thanks to the prevailing digital revolution, and advances in predictive analytics
and computing platforms, a new frontier has emerged to enhance the drug development process. We elucidate pertinent aspects of the use of real world evidence in regulatory settings, with emphasis on study design, analytical strategies, data quality
and regulatory requirements.
4:45 Real-World Evidence Complements and Supplements Clinical Trial Designs
David Van
Brunt, PhD, Senior Research Fellow and Head, HEOR Division of Evidence and Analytics AbbVie
Regulators, notably FDA, increasingly recognize that real-world data (RWD) can improve the efficiency and effectiveness of clinical trials and can strengthen the regulator’s understanding of the benefit-risk presentation of molecules under consideration
for approval. Use cases of RWD informing trial designs and being used in FDA decisions will be described, highlighting the diversity of RWD and its applications.
5:15 Improving Clinical Study Performance with Collaboration and Data during Protocol Development
Rob DiCicco, Deputy
Chief Health Officer, IBM Watson Health
Decisions made in clinical trial protocol design can have significant financial impacts during product development and commercialization. This session discusses the factors affecting protocol design and decision making and will present concrete ways
to leverage the power of collaboration and data to overcome these challenges.
5:45 Hi-Lo: Pragmatic Trial of Higher vs. Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis
Andy
MacKelfresh, Project Leader, Clinical Research Informatics, Duke Clinical Research Institute
The goal of this project is to determine whether less stringent control of serum phosphate versus the current standard approach will result in non-inferior rates of all-cause hospitalization among patients with ESRD undergoing hemodialysis. This presentation
will describe the trial design and approach leveraging eConsent, source data from eHR, harmonization of data from multiple sources, involvement of dietitians, and reporting.
6:15 Networking Reception (Regency Rotunda)
7:15 Close of Day
Friday, February 21
7:15 am Registration Open (Regency Rotunda)
7:45 BREAKFAST PRESENTATION: Breaking
Down the Roadblocks to Site Activation (Regency Ballroom T)
Jill
Johnston President, Study Planning & Site Optimization, WCG
8:15 Session Break
8:20 Chairperson’s Remarks
Wael
Salloum, PhD, CSO & Co-Founder, Mendel.ai
8:25 External Control Arms for Trial Development
David Tabano, PhD, MA, Associate Director, Center for Observational Research & Data Sciences (CORDS), Business Insights
& Analytics, Bristol-Myers Squibb
The presentation will summarise the key methodologies used for external controls, distributing those into categories where statistical adjustment is provided to generate external control groups, and those where more simplistic selection criteria
are applied to historic controls. For the purposes of this presentation, both techniques will fall under the remit of external study controls for consistency with regulatory and scientific literature surrounding this topic.
8:50 CASE STUDY: Use of Real-World Control Arm for Single Arm Trial Studies in Cancer
Jyotsna Mehta, Senior Director & Head, HEOR, Karyopharm Therapeutics
This case study will describe the definition of a real-world control arm, how to design a study using it alongside a single arm trial, and do’s and don’ts of this approach. It will provide examples of recently approved drugs and explain
the scenarios where such approaches can be used.
9:10 Chairperson’s Remarks
Lisa Henderson, MJH Life Sciences
9:15 Fox Insight: Driving Discovery with the Patient Voice
Lindsey
Riley, MPH, Senior Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson’s Research
Patient reported outcomes (PRO) data complements traditional clinical research with scale & accessibility, as well as patient-centricity. The Fox Insight (FI) study aims to gather the world’s largest dataset on the day-to-day experience
of living with PD, from 125,00 participants across the globe. This comprehensive dataset holds the power to help researchers better understand patients’ unmet needs, redefine therapeutic priorities and optimize clinical trial design.
9:35 Patient Advocacy Collaboration: A Value RWD Resource
Lisa Henderson, Editor of Applied Clinical Trials, MJH Life Sciences
9:55 Leveraging Real World Data in Clinical Trials and Observational Research, Focusing the Patient Experience
Claire Russell, Vice
President, Patient Experience, PRA Health Sciences
Real world evidence is underutilized in interventional and observational studies. As a result, protocols are less patient-centric; patient recruitment timelines are being extended and promising drugs are not reaching patients fast enough.
Due to this missed opportunity, patients are unable to access potentially life-saving treatment options.
10:25 Networking Coffee Break (Session Room Foyer)
10:55 Chairperson’s Remarks
Jyotsna Mehta, Senior Director & Head, HEOR, Karyopharm Therapeutics
11:00 Machine Learning with Real World Data
John Page, MD, ScD, Medical Director and Lead of Predictive Analytics, Center for Observational Research, Amgen
RWD provides opportunities to study drug utilization/safety of pharmaceutical products. Machine learning (ML) allows the development of automated algorithms for classification/prediction using data. ML offers opportunities to mine RWD for
classification of medical images and prediction of medical events. However, RWD currently has a number of limitations, including incomplete and faulty data. The performance of ML in RWD is discussed and some solutions are offered.
11:30 The Role of Emerging Technology in Improving the Patient Experience & Generating PROs
Chris Watson, PhD, Director, Product Strategy, Product Management, ERT
Real-World Data generated through Patient Reported Outcomes play an increasingly important role across the Drug Development Lifecycle. In a hyper-connected world, learn how patients’ own technologies enable effective ways of capturing
‘new data’ to deliver high-quality PROs
12:00 pm Transition to Shared Sessions
12:00 Chairperson’s Remarks
Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer
12:05 Re-Skilling for AI/ML: Leveraging Your SMEs
Nechama Katan, Associate Director, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer
AI/ML are very powerful tools for clinical trials. However, there is a gap between those that understand what AI/ML can do for the business and the business SME (subject matter experts) who really understand the business problems. Without
strong SME engagement in solutions, technical solutions are often at risk. This talk will review successful case studies for developing “lego” employees/teams who help bridge the gaps between AI/ML technologist and the
SMEs. We will discuss both the how and what that makes an AI/ML project successful in clinical trials.
12:25 PANEL DISCUSSION: AI Implementation: Technology, Data, People
Moderator: Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer
Panelists: Balazs Flink, PhD, Head, Clinical Trial Analytics, R&D Business Insights, Bristol-Myers Squibb
Abhishek Kadam, Associate Director, Data Operations, Clinical Data Management, Novartis
Malaikannan Sankarasubbu, Vice President, AI Research, Saama Technologies
Shameer Khader, PhD, Senior Director, Advanced Analytics, Data Science & Bioinformatics, AstraZeneca
It was proven that machine learning and AI can aid clinical development in various aspects. With evolving AI technology implementation challenges become more and more noticeable. This panel discussion will brainstorm the key pain points
of AI implementation:
- What is the best technology and how to work with technology providers?
- How to make all data machine learnable and available for AI applications
- How to solve “the people puzzle”
1:05 Transition to Lunch
1:10 SCOPE Send Off Luncheon Presentation: Proven, Pragmatic Applications of Artificial Intelligence in Safety Reporting
Steven Beales Senior Vice President, Safety Solutions Scientific & Regulatory Review WCG
1:40 Closing Remarks
1:45 SCOPE Summit 2020 Adjourns